LEXINGTON, Mass., Jun 04, 2010 (BUSINESS WIRE) –AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that
management will present at the following investor conferences during the
month of June:
Live webcasts of each presentation will be accessible through the
Investors section of the company’s website at www.amagpharma.com.
Following each conference, the webcast will be archived on the AMAG
Pharmaceuticals, Inc. website for approximately two weeks.
About AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that utilizes
its proprietary technology for the development and commercialization of
a therapeutic iron compound to treat iron deficiency anemia and novel
imaging agents to aid in the diagnosis of cancer and cardiovascular
disease. On June 30, 2009, AMAG received approval from the U.S. Food and
Drug Administration to market Feraheme(R) (ferumoxytol)
Injection for intravenous (IV) use for the treatment of iron deficiency
anemia in adult chronic kidney disease patients. For additional company
and product information, please visit www.amagpharma.com.
Feraheme is a registered trademark of AMAG Pharmaceuticals, Inc.
SOURCE: AMAG Pharmaceuticals, Inc.
Carol Miceli, 617-498-3361